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Objective: To reassess the relative potencies of teicoplanin and vancomycin following several years of clinical usage. 
Methods: The glycopeptide susceptibilities of clinical isolates of staphylococci collected from 70 hospitals in 1995 were 
determined using NCCLS (National Committee for Clinical Laboratory Standards) methods. 
Results: In total, 2885 isolates of Staphylococcus aureus and 1480 isolates of coagulase-negative staphylococci were 
collected. S. aureus was significantly less susceptible to vancomycin (MI& 1 mg/L) than teicoplanin (MIC~O 0.5 mg/L), 
but the reverse was the case for S. haemolyticus and S. epidermidis. No S. aureus isolate was resistant (232 mg/L) to 
either glycopeptide, but nine isolates of coagulase-negative staphylococci had an MIC of teicoplanin of 32 mg/L. 
Respiratory isolates of S. aureus were less susceptible to glycopeptides than those from other sites. Staphylococci from 
Belgium and Italy were less susceptible to teicoplanin than isolates from other countries. 
Conclusions: This European survey shows that in 10 years of clinical use there have been no major changes in the 
susceptibility of staphylococci to the glycopeptides. 
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INTRODUCTION 
The staphylococci are adept at colonizing and infecting 
patients in hospital, particularly those with impaired 
host defense, and can be transferred from person to 
person by hands or by fomites through the air. 
Staphylococcus aureus is a common cause of soft tissue 
infection, e.g. impetigo, cellulitis, or wound infection, 
and causes osteomyelitis, arthritis, bacteremia with 
metastatic infection, and the scalded skin and toxic 
shock syndromes [l]. Septicemia and endocarditis carry 
a high mortality, up to 71% in one series of 119 patients 
with endocarditis [2]. Although normal residents of 
slun, the coagulase-negative staphylococci have become 
increasingly important causes of nosocomial bacteremia 
associated with invasive monitoring, intravascular cath- 
eters and prosthetic heart valves or joints. S. epidermidis 
produces a polysaccharide slime which allows the 
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organism to avoid host defenses and cause a persistent 
foreign body infection [3]. 
Most staphylococci produce p lactamase and are 
resistant to penicillin. An increasing proportion of strains 
of S. aureus have intrinsic resistance to methicillin and 
present major problems for hospitals in the control of 
cross-infection. Among the coagulase-negative staphyl- 
ococci, particularly those acquired in hospital, multiple 
antibiotic resistance is common [4]. The glycopeptides, 
teicoplanin and vancomycin, are the antibiotics of first 
choice for treatment of these infections and are an 
alternative to flucloxacillin and nafcillin in penicillin- 
allergic patients. 
Teicoplanin and vancomycin have simdar activity 
against rnethicillin-sensitive isolates of S. aureus, although 
the MIC of teicoplanin for some strains can rise to 16 
mg/L [5,6]. Teicoplanin is more active than vanco- 
mycin against methicillin-resistant isolates of S. aureus 
(MRSA) [7-111. Against the characterized vancomycin- 
resistant and vancomycin-heteroresistant S. aureus strains 
(vancomycin MIC=8 mg/L), recently isolated in Japan 
[12], the USA [13] and France [14], teicoplanin 
displayed MICs ranging fiom 8 to 32 mg/L 1151. 
Teicoplanin is usually less active than vancomycin 
against the coagulase-negative staphylococci, and the 
organisms have a wide range of susceptibilities [16,17]. 
547 
548 Clinical Microbio logy and Infection, Volume 5 Number  9,  September 1999 
However, epidemiologic analysis using pulsed-field gel 
electrophoresis shows that reports of resistance in 
staphylococci are often exaggerated because of epidemic 
spread of one or more resistant strains [18]. Against S. 
huemolyticus, teicoplanin is four-fold less active than 
vancomycin [19]. Other species of staphylococci show 
similar susceptibilities for both glycopeptides. 
METHODS AND STUDY DESIGN 
In 1995, 70 laboratories in nine European countries 
were each asked to provide 100 consecutive Gram- 
positive isolates which had been identified and tested 
for susceptibility to a range of antibiotics. Patients were 
not ambulatory, and multiple isolates from the same 
patient were not permitted. Susceptibility in vitro was 
assessed locally by the usual laboratory method and at 
a coordinating center in each country according to 
NCCLS guidelines [20]. The coordinators and number 
of laboratories were as follows: Belgium, L. Verbist (7); 
France, C.J. Soussy (8); Germany, A. Bauernfeind (9); 
Italy, G.C. Schito (10); The Netherlands, J. Degener 
(5); Portugal, J. Melo-Cristino (5); Spain, E Baquero 
(9); Switzerland, R. Auckenthaler (8); UK, D. 
Felmingham (9). Each coordmating laboratory par- 
ticipated successfdly in a quality assessment scheme to 
ensure comparability of MIC data [21]. Any strains 
suspected of being glycopeptide-resistant were sent to 
the Lepetit Research Centre (an affiliate of Marion 
Merrell Dow Research Institute) in Gevenzano, Italy 
for re-identification and retesting. 
Differences between distributions of MICs were 
tested by a chi-square test with Yates’ correction or 
Fisher’s exact test where numbers were small [22]. 
These tests were intended to be descriptive and not to 
suggest underlying mechanisms for the differences. 
Isolates &om Merent sites, for example, would often 
not be expected to have MICs independent of each 
other, but the degree of relatedness is not known. 
Among a total of 6,824 Gram-positive strains [27], 
2885 isolates of S. uureus and 1480 isolates of coagulase- 
negative staphylococci were collected, of which 2852 
and 1444, respectively, were retested at a coordinating 
laboratory. For S. aureus, the mode MIC of vancomycin 
(1 mg/L) was significantly higher than that of teico- 
planin (0.5 mg/L) (x2=1015 df5, p<0.0005), despite a 
smaller range of values (Table 1). MRSA was not 
separated from other strains at most centers. However, 
the 91 isolates reported had similar sensitivity to 
teicoplanin as other staphylococci (MIC50 1 mg/L, 
MIC90 4 mg/L). 
Unspeciated coagulase-negative staphylococci 
(x2=135 df 4, p<O.OOl), S. epidermidis (x2=360 df 5, 
p<O.OOl) and S. huemolyticus (x2=34 df 2,  p<O.OOl) 
were less susceptible to teicoplanin than vancomycin 
(Tables 2-4). Teicoplanin was less active against S. 
huemolyticus than S. epidermidis (x2=29 df 6, p<O.OOl). 
With respect to other identified species of coagulase- 
negative staphylococci, S. warnerii and S. lugdunensis 
displayed the highest and the lowest MIC9o of teico- 
planin: 8 and 0.5 mg/L, respectively (Table 5). Vanco- 
mycin MIC90 values &d not vary among the species 
considered. 
No S. uureus isolates were resistant to teicoplanin 
or vancomycin accordmg to the NCCLS guidelines 
(232 mg/L). Resistance was rare among the coagulase- 
negative staphylococci. Of nine isolates with a teico- 
planin MIC of 32 mg/L, four were unspeciated, two 
Table 1 In vitro susceptibility of isolates of Staphylococcus aureu5 &om nine countries to glycopeptides 
Teicoplanin Vancomycin 
MICSO MICw Range MICso MICw Range 
Country No. (mgm (mg/L) (mg/L) (mgW ( m g 4  (mgW 
Belgium 289 1 4 10.12-16 1 2 0.5-4 
France 346 0.5 1 10.12-8 1 1 0.5-2 
Germany 282 0.5 1 10. 12-8 0.5 1 10.12-4 
The Netherlands 204 0.5 0.5 10.12-2 1 1 0 .51  
I d Y  428 1 4 10.1243 1 2 0.25-4 
PomgaI 187 1 4 10.12-8 1 2 0.25-4 
Spain 294 0.5 0.5 <0.12-4 1 2 0.25-2 
Switzerland 303 0.5 1 10.124 1 2 10.124 
UK 519 1 1 0.25-4 1 1 0.5-2 
All 2852 0.5 2 S0.12-16 1 2 10.12-4 
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Table 2 In vitro susceptibility to glycopeptides of isolates of unspeciated coagulase-negative staphylococci from nine 
countries 
No. Country 
Belgium 
France 
Germany 
The Netherlands 
Italy 
Spain 
Switzerland 
UK 
All 
39 
41 
40 
80 
12 
23 
73 
52 
360 
2 
2 
0.5 
1 
1 
0.25 
1 
2 
8 
16 
0.5 
4 
8 
2 
2 
4 
10.12-16 
0.25-32 
0.25-4 
10.12-16 
10.12-8 
10 .124  
10 .124  
0.25-32 
1 
2 
0.5 
1 
2 
0.5 
2 
2 
2 
2 
0.5 
2 
4 
2 
2 
2 
0.25-4 
1 -4 
0.5-1 
0.25-2 
0 . 5 4  
10.12-2 
10 .124  
0.5-4 
1 4 10. 12-32 1 2 $0.124 
Table 3 In vitro susceptibility to glycopeptides of isolates of Staphylococcus epidermidis from nine countries 
Teicoplanin Vancomycin 
MICso MICw Range MIC5o MIC9o Range 
Country No. (mg/L) (mgm (mg/L) (mg/L) (mg/L) (mg/L) 
Belgium 87 2 8 0.5-16 2 2 0 . 5 4  
France 120 2 8 0.25-32 2 2 0.25-8 
Germany 143 0.5 4 10.12-16 0.5 2 go. 12-2 
The Netherlands 33 1 2 0.25-8 1 1 0.5-2 
Italy 124 2 8 10.12-1 6 2 2 0.25-4 
Portugal 124 2 8 0.25-16 2 2 0.5-4 
Spain 134 0.5 2 10.12-4 1 2 0.25-2 
Switzerland 38 1 4 10.12-16 2 2 0 . 5 4  
UK 35 2 4 0.5-8 2 4 1 4  
All 838 1 8 10.12-32 2 2 10.12-8 
Table 4 In vitro susceptibility to glycopeptides of isolates of Staphylococcus haemolyticus from nine countries 
Teicoplanin Vancomycin 
MICso MICw Range MICso MIC9o Range 
Country No. (mg/L) (mgm (mg/L) (mg/L) (mg/L) (mg/L) 
Belgium 
France 
Germany 
The Netherlands 
IdY 
Portugal 
Spain 
Switzerland 
UK 
6 
14 
4 
1 
29 
21 
11 
3 
2 
8 
2 
32 
8 
4 3 2  
0.25-8 
0.5-32 
0.5 
10. 12-1 6 
0.25-16 
0.25-16 
2-8 
4-32 
1 
2 
- 
2 
2 
- 
1-2 
1-4  
0 . 5 4  
1 
0.5-4 
1-4 
1-2 
1-4 
1 4  
All 91 2 8 10.1 2-32 1 2 0 . 5 4  
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Table 5 In vitro susceptibility of minor species of coagulase-negative staphylococci 
Teicoplanin Vancornycin 
MICso MIC9o Range MICso MICw Range 
Country No. (mg/L) (mgm (mg/L) ( m g 4  ( m g 4  (mg/L) 
Staphylococcus capifis 26 0.5 2 10.12-8 1 2 0.25-4 
S. caprae 1 - - 10.12 - 
S. mhnii 8 2 4 0 . 5 4  2 2 1-2 
S. hominis 40 0.5 4 10.12-8 1 2 0.25-4 
S. kloosii 1 
- 1 
2 - - - 8 - 
S. lugdunensis 8 0.5 0.5 0.25-0.5 2 2 0.25-2 
S. saprophytim 25 1 4 0.5-4 2 2 0.5-2 
S. schlei$ri 3 0.5-2 - 
s. sciuri 1 
S. simulans 21 0.5 4 10.12-8 1 2 1-4 
S. warnerii 17 1 8 10.12-16 1 2 0.5-4 
s. rylosus 4 - 0.25-2 - 
- - - 1-2 
- 4 - - 8 - 
- - 0.5-2 
were S. epidermidis and three were S. haemolyticus. Five 
of these isolates came from France. For vancomycin, 
two isolates of S. epidermidis from France were found to 
have an MIC of 8 mg/L (intermediate). 
The MICs for S. aureus isolates from blood were 
significantly higher than those for isolates from the 
urinary tract (x2=13 df5, p<0.03) or skin (x2=21 df6, 
p<0.005), but significantly lower than those for isolates 
fiom the respiratory tract (x2= 14 df 6, p<0.05). The 
percentages of isolates with teicoplanin MICs 24 mg/L 
were 7% (27/393) from blood, 2% (3/135) from urine, 
11% (80/725) fiom the respiratory tract, 4% (50/1362) 
from skin and 7% (3/41) from the gastrointestinal tract. 
Isolates from blood were significantly less susceptible to 
vancomycin than those from urine, respiratory tract or 
skin (x2 test, p<0.005). A vancomycin MIC 10.5 mg/L 
was observed for 18% (72/393) of blood isolates, 32% 
(44/135) ofurine isolates, 29% (21 1/725) of respiratory 
isolates, 25% (338/1362) ofskin isolates and 27% (1 1/41) 
of gut isolates. The proportion of MICs 24 mg/L was 
1-2% irrespective of site. 
The teicoplanin MICs of unspeciated coagulase- 
negative staphylococci and S. epidermidis isolates from 
blood were significantly higher than those of skin 
isolates, but were similar to all other sites (x2=51 df7, 
p<O.OOl; x2=41 df6, p<O.OOl). 
An MIC 28 mg/L was found for 12% of blood 
isolates of either group (91/760 and 54/433, respec- 
tively), but for only 7% of skin isolates (18/284 and 
121165, respectively). For S. haemolyticus, the propor- 
tion ofisolates with an MIC 28 mg/L was 25% (16/65) 
for blood, urinary and respiratory isolates, but only 6% 
(1116) for skin isolates. There were no significant 
Werences in vancomycin MICs by site. 
A significantly higher proportion of S. aureus 
isolates had a teicoplanin MIC 24 mg/L in Belgium 
(44/289, 15%), Italy (821428, 19%) and Portugal 
(33/187, 18%) than in the remaining countries 
(16/1948, 0.8%) (x2 test, p<0.0005). Blood, respiratory 
and skin isolates from these three countries all showed 
a significantly higher proportion with MICs 24 mg/L. 
A similar difference was observed with vancomycin 
MICs only with respect to Italy (36/428, 8% versus 
2/1948, 0.1%, p<O.OOl Fisher’s test). No isolates had 
an MIC 28 mg/L. 
For unspeciated coagulase-negative staphylococci, 
there was a significantly higher proportion of isolates 
with a teicoplanin MIC 28 mg/L in Belgium (6/39, 
15%), France (9/41, 22%), The Netherlands (7/80, 
9%), Italy (2/12, 17%) and the UK (4/52,8%) than in 
other countries (0/136, 0%) (p<0.02 Fisher’s test). 
Blood isolates fiom Belgium, France, Italy and Portugal 
(p<O.OOl x2 test), urine isolates from Belgium and 
Germany (p<O.Ol, Fisher’s test) and shn isolates fiom 
Belgium, Italy, Portugal and France (p<0.04, Fisher’s 
test) were significantly more likely to have an MIC 
28 mg/L when results were pooled than those &om the 
other countries pooled. Only one isolate had a vanco- 
mycin MIC 28 mg/L. 
S. epidermidis isolates from Belgium (14/87, 16%), 
France (20/120, 17%), Italy (25/124, 20%) and 
Portugal (17/105, 16%) were more likely to have a 
teicoplanin MIC 28 mg/L than in the other countries 
(101383, 2.6%) (p<O.OOl x2 test). Isolates from blood 
and skin showed the same pattern of significant 
differences (p<O.OOl, Fisher’s test), but for urinary 
isolates, only those from Germany (5/22) and 
Belgium (4/15) were more likely than the rest to have 
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an MIC 28 mg/L (p=0.04, Fisher’s test). There was 
no significant difference between the countries with 
respect to vancomycin sensitivity. The proportion of 
S. haemolyticus isolates with a teicoplanin MIC 28 
mg/L was similar in each country, with the exception 
of Belgium (4/6 versus 15/85, p=0.03, Fisher’s test). 
There were insufficient isolates to allow comparison 
of sites. 
There were significantly more discrepancies in 
susceptibility testing of teicoplanin than with vanco- 
mycin (S. aureus, 27/2560, 1.1% versus 3/2660, 0.1%, 
p<O.001; coagulase-negative staphylococci, 80/1273, 
6.3% versus 13/1277, 1.0%, p<O.001). The most usual 
error was an isolate being reported as having 
intermediate sensitivity at the local laboratory, but as 
sensitive at the coordinating center. This error was 
probably because the distribution of teicoplanin MICs 
was wider than that of vancomycin (Table 1). For S. 
aureus, the discrepancy was significantly more likely at 
Swiss centers than elsewhere (7/303 versus 1612298, 
x2=10.3, p<O.01). 
For coagulase-negative staphylococci, not only 
were teicoplanin-sensitive isolates initially reported as 
intermediate/resistant (54/1273, 4.2%), but inter- 
mediate/resistant strains were reported as teicoplanin 
sensitive (26/1273, 2%). Discrepancies were most 
frequent in The Netherlands, France and Italy. Major 
hfferences, i.e. sensitive at one laboratory and resistant 
at the coordinator, occurred in six cases (0.4%) each 
way, comprising S. haemolyticus (three cases), S. epider- 
midis (five cases) and unspeciated staphylococci (four 
cases). Four cases involved blood isolates. Most errors 
in vancomycin susceptibility testing were reported from 
Germany; 11 of 32 isolates of unspeciated coagulase- 
negative staphylococci from various sites were 
incorrectly reported as resistant. 
With the use of disk methods, susceptible isolates 
of S. aureus were more likely to be classified wrongly as 
resistant or intermediate to teicoplanin than were 
resistant isolates as susceptible (14/1798 versus 4/1798, 
p=0.004, Fisher’s test). False-resistant results were also 
found using ATB MICs (4/66, 6%), microdilution 
MICs (2/255, 0.8%), Sceptor MICs (2131, 7%), and 
Etest MICs (1/167, 0.6%). 
For coagulase-negative staphylococci, the ATB 
MIC method at a local laboratory performed least well 
and was more likely to classifjr susceptible or 
intermediate isolates as resistant (or susceptible as 
intermediate) than to find resistant isolates susceptible 
(10/41 versus 0/41, x2=8, p<O.Ol). NCCLS and other 
disk methods (6/181,3%; 23/592,4%) and agar and E 
test MIC methods (6163, 10%; 6/31, 19%) also pro- 
duced false-resistant results. False susceptibility was most 
often reported with Rosco and other &sk methods 
(8/159, 5%; 17/685, 2.5%). For S. epidermidis, false- 
resistant results were produced most often by NCCLS 
and other disk methods (5/153, 3.3%; 15/377, 4%), 
Etest (5/26, 19%) and ATB (4/21, 19%). Incorrect 
susceptibility was reported most frequently with Rosco 
and other disk methods (4/67, 6%; 10/463, 2.2%). For 
S. haemolyticus, a false-resistant result was produced by 
the ATB MIC method in six (75%) of eight cases, 
compared with two of 15 cases by microdilution MIC 
or two of 30 by NCCLS disk methods. 
Nine isolates (comprising three S. epidermidis, three 
S. haemolyticus, one S. warnerii, one S.  hominis and one 
unspeciated coagulase-negative staphylococcus) with a 
teicoplanin MIC of 16 mg/L at the coordinating 
laboratory were referred to the central laboratory at 
Geranzano. On repeat testing, the MIC for these strains 
was found to be between 0.5 and 32 mg/L (median 16 
mg/L) for teicoplanin and 1-4 mg/L (median 2 mg/L) 
for vancomycin. 
DISCUSSION 
Nosocomial infections caused by multiply-resistant 
Gram-positive pathogens are an increasing cause of 
concern, particularly in immunocompromised patients 
[23,24]. ‘Last-resort’ antimicrobial combinations, which 
include vancomycin and teicoplanin, are able to cover 
these difficult-to-treat strains. However, coagulase- 
negative staphylococci with a teicoplanin MIC 
216 mg/L have been described, while even more 
disturbing is the recent recognition in Japan, in the 
USA and in France of S. aureus isolates with reduced 
susceptibility to vancomycin [12,13,14,25,26]. 
This survey represents the largest collection of 
staphylococcal isolates to be tested for susceptibility to 
both glycopeptides. The overall results are similar to 
those obtained when teicoplanin and vancomycin were 
first compared in the 1980s. Teicoplanin continues to 
have a wider range of MICs for staphylococci than for 
vancomycin. For S. aureus, although the concentration 
of each glycopeptide required to inhibit 90% of the 
strains was 2 mg/L, comparison of the distribution of 
MICs showed that teicoplanin was significantly more 
active. Teicoplanin was less active against coagulase- 
negative staphylococci than vancomycin and was least 
active against S. haemolyticus. 
MRSA were not separated from other strains at 
most centers, with the exception of 91 MRSA isolates 
that had similar teicoplanin MIC50 and MICm values 
(one-fold higher) to those of methicillin-sensitive 
isolates. These results are similar to other data obtained 
fiom an additional study on isolates collected in the 
Itahan centers [27]. 
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According to NCCLS guidelines, no resistance of 
S. aureus to teicoplanin was detected, but lugher MICs 
were found in isolates fiom Belgium, Italy and Portugal 
than elsewhere, irrespective of methodology. Isolates of 
vancomycin-resistant S. aureus, as described first &om 
Japan [12,25], were not collected, although current 
detection methods for the hetero-resistant strains are 
not optimal and they may have been missed during the 
present study. Only nine (0.6%) isolates of coagulase- 
negative staphylococci were resistant to teicoplanin, 
which is reassuring. Disk susceptibility testing pro- 
duced false-resistant results in 5% of cases, but dis- 
crepancies rose to 19% for the Etest and ATB methods, 
throwing into doubt their validity for local laboratory 
use. 
Disk susceptibility testing of teicoplanin can be 
unreliable because of slow diffusion of the molecule in 
agar and the poor correlation between MIC and the 
diameter of the zone of inhibition. Vancomycin dl&ses 
more readily, with over 70% of the contents of a disk 
having entered the medium afier incubation for 6 h, 
compared with 25% for teicoplanin [28]. Inoculum size 
can easily afEect the reporting of an isolate as susceptible 
or resistant, and up to 16-fold differences in the MIC 
for S. aureus have been observed when the inoculum is 
increased [29]. Raising the inoculum h m  5X103 
organisms to 5 X lo5 organisms does not alter the MIC 
of vancomycin for methicdbn-resistant coagulase- 
negative staphylococci, but increases the of teico- 
planin to 32 mg/L [7]. Variations in the medium and 
incubation period affect the MIC of teicoplanin more 
than that of vancomycin [30]. 
If NCCLS criteria are used for S. aureus, only 1% 
errors between MIC and &sk diffusion would be 
expected [31]. The ATB and Sceptor MIC methods 
performed poorly in comparison, with errors for 6 7 %  
of isolates. In an earlier study of 105 strains of S. 
haemolyticus, 33 were susceptible by disk testing and 
intermediate by MIC, seven were resistant by disk and 
intermediate by MIC, and 10 were resistant by MIC 
but susceptible by disk [19]. The Etest uses difision of 
an antibiotic gradlent fiom a plastic strip, but produced 
false-resistant results for 19% of isolates [32]. The ATB 
method was the most likely method to classify sensitive 
isolates as resistant, including 19% of S. epidermidis and 
75% of S. haemolyticus, raising doubts that either 
method is suitable for susceptibility testing of these 
species. However, the reasons for poor performance 
may be methodological rather than systematic. 
Acknowledgment 
This study was supported in part by an educational 
grant h m  Marion Merrell Dow Europe AG, Switzer- 
land. 
References 
1. Waldvogel FA. Staphylococcus aurevs (including toxic shock 
syndrome). In Mandell, Douglas and Bennett’s principles and 
practice of infectious diseases, 4th edn. New York Churchill 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16 
17 
Livingstone 1995: 175476. 
Frimodt-Moller N, Espersen F, Rosdahl VT. Antibiotic 
treatment of Sfaphylococnrs aureus endocarditis. Acta Med Scand 
Archer GL. Staphylococcus epidermidis and other coagulase- 
negative staphylococci. In Mandell, Douglas and Bennett’s prin- 
ciples and practice of infectious diseases, 4th edn. New York: 
Churchill Livingstone 1995: 177744. 
Gold HS, Moellering Jr RC. Antimicrobial drug resistance. N 
Engl J Med 1996; 335: 1445-53. 
Gorzynski EA, Amsterdam D, Beam TR, Rotstein C. Compar- 
ative in vitro activities of teicoplanin, vancomycin, oxacillin and 
other antimicrobial agents against bacteremic isolates of Gram- 
positive cocci. Antimicrob Agents Chemother 1989; 33: 2019- 
22. 
Fitch L, Johnson A. Reduced susceptibility to teicoplanin in a 
methicillin resistant strain of Staphylococnrs aureus. J Antimicrob 
Chemother 1998, 41: 578. 
French GL, Ling J, Ling T, Hui YW. Susceptibility of Hong 
Kong isolates of methcillin-resistant Staphylococcus aureus to 
antimicrobial agents. J Antimicrob Chemother 1988; 21: 581-8. 
Maple PAC, Hamilton-Miller JMT, Brumftt U? Comparative 
in-vim activity of vancomycin, teicoplanin, ramoplanin (form- 
erly A16686). palimycin, DuP 721 and DuP 105 against 
methicillin and gentamicin-resistant Staphylococcus aureus. 
J Antimicrob Chemother 1989; 23: 517-25 
Bezian MC, Ribou G, Masquelier B. ActivitC in vitm de la 
vancomycine et de la teicoplanine sur les cocci Gram +. Path01 
Biol 1992; 40: 461-5. 
Mini E, Novelli A, Mazzei T, Periti F’. Comparative in vitm 
activity of the new oxazolidinones DuP 721 and DuP 105 against 
staphylococci and streptococci. Eur J Clin Micmbiol Infect Dis 
1989; 8: 256-60. 
Del Bene V, John JF, Twitty JA, Lewis JW Anti-staphylococcal 
activity of teicoplanin, vancomycin and other antimicrobial 
agents: the significance of methicillin resistance. J Infect Dis 
1986; 154: 349-52. 
Hiaramatsu K, Hanaki H, In0 T, Yabuta K, Oguri T, Tenover 
FC. Methcillin resistant Staphylococcus aureus clinical strain with 
reduced vancomycin susceptibility. J Antimicrob Chemother 
1997; 40: 135-6. 
Centers for Disease Control and Prevention. Staphylococcus aureus 
with reduced susceptibility to vancomycin. United States, 1997. 
MMWR 1997; 46: 624-6. 
Ploy MC, Gslaud C, Martin C, de Lumley L, Denis E First 
clinical isolate of vancomycin-intermehate Staphylocom aureus 
in a French hospital. Lancet 1998; 351: 1212. 
Tenover FC, Lancaster MV, Hil BC et al. Characterization of 
staphylococci with reduced susceptibility to vancomycin and 
other glycopeptides. J Clin Microbiol 1998; 36: 1020-7. 
Bauernfeind A, Petermiiller C. In vim activity of teichomycin 
A 2 in comparison with penicillin and vancomycin against 
Gram-positive cocci. Eur J Clin Microbiol 1982; l(5): 278-81. 
Kobayashi H, Okuzumi K. In vitro activity of teicoplanin. 
Nippon Kagaku Ryoho Gakkai Zasshi 1993; 4l(suppl 2): 
216-18. 
1987; 222: 175-82. 
18. Goering KV, Fey PD, Goldstein Fw. Usefulness of pulsed-field 
gel electrophoresis in the epidemiological analysis of S. aureus 
isolates with decreased susceptibility to teicoplanin. Eur J Clin 
Microbiol Infect Dis 1995; 14(suppl 1): S S 5 .  
Schito e t  al: European survey of glycopeptide susceptibi l i ty:  Staphylococcus spp. 5 5 3  
19. Low DE, McGeer A, Poon R .  Activities of daptomycin and 
teicoplanin against Staphylococcus huemolyticus and Staphylococcus 
epidermidis, includmg evaluation of susceptibility testing recom- 
mendations. Antimicrob Agents Chemother 1989; 33: 585-8. 
20. National Committee for Clinical Laboratory Standards. 
Performance standards for antimicrobial susceptibility testing. 
Sixth informational supplement. NCCLS document M10GS6, 
Vol. 15, No 4. Wayne, Pennsylvannia: NCCLS, 1987. 
21. Brown DFJ, Courvalin P. European Glycopeptide Resistance 
Group. Quahty assessment of glycopeptide susceptibility tests: a 
European collaborative study. Int J Antimicrob Agents 1998; 9: 
15343. 
22. Armitage P, Berry G. Statistical methods in medical research. 2nd 
edn. London: Blackwell Scientific Publications, 1991. 
23. Spencer RC.  Epidemiology of infection in ICUs. Intens Care 
Med 1994; 2O(suppl4): 2 4 .  
24. Griineberg R N ,  Wilson AE? Anti-infective treatment in intensive 
care: the role of glycopeptides. Intens Care Med 1994; 20(suppl 
25. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in 
Japanese hospitals of strains of Staphylococcus atlieus hetero- 
geneously resistant to vancomycin. Lancet 1998; 350: 1670-3. 
4): 17-22. 
26. Sieradzki K, Roberu RB, Haber SW, et al. The development of 
vancomycin resistance in a patient with methicillin-resistant 
Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23. 
27. Marchese A, Debbia E, Bacca D, Bahstreri G, Musolino B, 
Schito GC. Multidrug-resistant Gram-positive pathogens. An 
update on current microbiological patterns. Drugs 1997; 
54(suppl 6): 1-54. 
28. Cavenaghi LA, Biganzoli E, Danese A, Parenti E Diffusion of 
teicoplanin and vancomycin in agar. Diagn Microbiol Infect Dis 
29. Greenwood D. Microbiological properties of teicoplanin. 
J Antimicrob Chemother 1988; 2l(suppl A): 1-13. 
30. Johnson AP, Uttley AHC, Woodford N, George RC. Resistance 
to vancomycin and teicoplanin: an emerging clinical problem. 
Clin Microbiol Rev 1990; 3: 280-91. 
31. Kenny MT, Mayer GD, Dulworth JK, Brackman MA, Farrar K. 
Evaluation of the teicoplanin broth microdution and disk 
diffusion susceptibility tests and recommended interpretative 
criteria. Diagn Microbiol Infect Dis 1992; 15: 60P-12. 
32. Spencer RC,  Goering R .  A critical review ofthe in vitro activity 
of teicoplanin. Int J Antimicrub Agents 1995; 5: 169-77. 
1992; 15: 253-8. 
